Skip to content
Aperlena

Germany - Medicines - Open-House biosimilar discount contracts 2026-02 - Interferon beta 1a (finished medicinal product: Rebif (R))

Original Deutschland - Arzneimittel - Open-House-Biologika-Rabattverträge 2026-02 - Interferon beta 1a (Fertigarzneimittel: Rebif (R))

Open Contract notice

Key facts

Closes in
550 days
Where
Germany Hamburg
Procedure
Open procedure Anyone may submit a bid, in one step, with no pre-selection. Full entry Above the EU threshold A contract large enough that EU-wide rules apply and it must be published on TED. Full entry
CPV code The EU's common vocabulary for what is being bought: an eight-digit code every notice carries. Full entry
33600000 Pharmaceutical products
Original language
German
Source
via TED - Tenders Electronic Daily (Publications Office of the EU), verified 1 month ago
Notice number
96137-2026
Watch this tender

If the deadline moves or the notice is corrected, we email you. Log in

  1. Published
  2. Today
  3. Deadline open for 780 days
  4. Awarded pending

Summary

Machine-generated summary

German statutory health insurance funds are seeking discount contracts under Section 130a paragraph 8 SGB V for the active substance Interferon beta 1a, finished medicinal product Rebif (R), and under Section 130c paragraph 1 SGB V. The procedure is an open-house model: identical conditions apply to all participants, no individual negotiations take place, and no exclusivity is granted. Contracts run for a maximum of 24 months starting 1 April 2026 and end at the latest on 31 March 2028 regardless of the signing date. Pharmaceutical entrepreneurs may join at any time during the contract term. Further details are in the participation and contract documents.

Description

Die beteiligten Kassen verfolgen das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zu dem Wirkstoff Interferon beta 1a (Fertigarzneimittel: Rebif (R)) zu schließen. Der Vertragsschluss erfolgt im Rahmen des Open-House-Biologika-Verfahrens der beteiligten Kassen: Individuelle Verhandlungen über Vertragsinhalte werden nicht geführt, es gelten einheitliche Konditionen. Die beteiligten Krankenkassen sichern einzelnen Vertragspartnern keine Exklusivität zu. Die Vertragslaufzeit beträgt maximal 24 Monate beginnend mit dem 01.04.2026. Der Vertrag endet spätestens am 31.03.2028, unabhängig vom Datum des Vertragsschlusses. Ein Beitritt zu diesem Open-House-Verfahren ist innerhalb der Vertragslaufzeit jederzeit möglich. Die gemachten Angaben zur Bindefrist sind vorliegend nicht relevant und ausschließlich den zwingenden Vorgaben des Formulars geschuldet Alle weiteren Informationen sind den Teilnahme- und Vertragsunterlagen zu entnehmen. Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130c Abs. 1 SGB V zu dem Wirkstoff Interferon beta 1a (Fertigarzneimittel: Rebif (R)) im Rahmen eines Open-House-Verfahrens.

Can I bid?

  • Open procedure: any interested supplier may submit a bid. Above the EU threshold: open to companies from any EU country.
  • The notice is written in German.
  • Certificates from another EU country? Check the equivalents on eCertis

Official source

Source: TED - Tenders Electronic Daily (Publications Office of the EU)

Always verify details on the official notice.

Last verified against TED - Tenders Electronic Daily (Publications Office of the EU) 1 month ago

More from this buyer

Full buyer profile

52 open tenders right now

This buyer has no award history in this sector yet. Usual winners, Medical equipment & pharmaceuticals - Germany

Company Wins Total awarded Last win
Siemens Healthineers AG 42 €17.4M Sep 2026
Philips GmbH 20 €5.3M Sep 2026
GlaxoSmithKline GmbH & Co. KG 15 n/a Sep 2026
ASTRAZENECA GMBH 12 n/a Jul 2026
Brainlab Sales GmbH 11 €4.9M Sep 2026

Based on 1019 awards with a linked company profile over the last 2 years.

Change history

Every time an official source republished this notice with different content. We watch every source we index, including regional copies of the same notice.

  1. Act now
    • Submission deadline: Moved 1 day EARLIER: now March 31, 2028, 00:00
    • Scope and criteria: The description was expanded. Re-read it before you bid.

Follow this tender and we email you the moment it changes. Create account

Similar tenders

Market context

Avg. open tender · Medical equipment & pharmaceuticals
€10,063,485
9,570 open across Europe right now
Buyer track record on Aperlena
55 notices tracked · 0 awarded

Never miss a tender like this

58 new notices in Medical equipment & pharmaceuticals in Germany in the last 7 days. Get an email when new ones appear. Free.

Set up my alert

550 days left

Open notice

Keyboard shortcuts

Read a list without reaching for the mouse. The shortcuts stay quiet while you type in a field.

j
Next result
k
Previous result
Enter
Open the result
n
Next page
p
Previous page
c
Compare this result
s
Shortlist this result
/
Search from any page
Ctrl K
Search from any page
?
Show these shortcuts
Esc
Close

Index

Close
Log in

Language